First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

The issuer is solely responsible for the content of this announcement.

Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round Novo Holdings and Jeito Capital co-led the ...

Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity ...

Clario, a leading provider of endpoint data solutions to the clinical trial industry, today announced they have acquired ...

I think that there are some somewhat inconsistent comments in the Sixth Circuit decision that I see as tiptoeing around an ...

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

Clario, a leading provider of endpoint data solutions to the clinical trial industry, today announced they have entered into ...

Novo Nordisk owns Novo Holdings, the majority shareholder of Novo Nordisk, the Danish pharmaceutical company that develops and sells the weight-loss drug Ozempic. In a statement, the foundation ...

The reigning MLS Cup champions are bottom of the league, so it's little wonder the Galaxy are tumbling down the order of ESPN's MLS Power Rankings.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novo Nordisk fell on Monday on a second set of worse than expected trial results for the latest ...